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ABSTRACT
The transcriptional coactivator peroxisome proliferator activated receptor  coactivator 1
(PGC-1) can activate a number of transcription factors to regulate mitochondrial biogenesis and
cell-specific responses to cold, fasting, and exercise. Recent studies indicate that PGC-1 knock-
out mice exhibit behavioral abnormalities and progressive vacuolization in various brain regions.
To investigate the roles for PGC-1 in the nervous system, we evaluated the temporal and
cell-specific expression of PGC-1 in the normal developing rat brain. Western blot of whole brain
homogenates with a PGC-1-specific antibody revealed that PGC-1 protein was most abundant
in the embryonic and early postnatal forebrain and cerebellum. Using quantitative reverse-
transcriptase polymerase chain reaction (RT-PCR), we determined that PGC-1 mRNA expres-
sion increased most markedly between postnatal days 3 (P3) and 14 in the cortex, striatum, and
hippocampus. Immunohistochemical and immunofluorescence analyses of brain tissue indicated
that while PGC-1 was found in most neuronal populations from embryonic day 15 to P3, it was
specifically concentrated in GABAergic populations from P3 to adulthood. Interestingly, PGC-1
colocalized with the developmentally regulated chemoattractant reelin in the cortex and hip-
pocampus, and the survival-promoting transcription factor myocyte enhancing factor 2 was
highly concentrated in GABAergic populations in the striatum and cerebellum at times of
PGC-1 expression. These results implicate PGC-1 as a regulator of metabolism and/or survival
in GABAergic neurons during a phase of mitochondrial and synaptic changes in the developing
brain and suggest that PGC-1 may be a good target for increasing metabolism in GABAergic
populations in neurodevelopmental and neurodegenerative disorders. J. Comp. Neurol. 502:1–18,
2007. © 2007 Wiley-Liss, Inc.
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With the discovery that mutations in transcriptional
repressors or coactivators can be causative for neurode-
velopmental disorders such as Rett’s syndrome and
Rubinstein-Taybi syndrome (MeCP2 and CREB-binding
protein, respectively; Petrij et al., 1995; Amir et al., 1999;
Hong et al., 2005), research on the transcriptional control
of postnatal brain development has come to the forefront.
In this article we present another potential player in the
transcriptional control of development: peroxisome prolif-
erator activated receptor  (PPAR) coactivator 1 (PGC-
1). Initially described as a transcriptional coactivator of
PPAR and mediator of adaptive thermogenesis in adi-
pose tissue (Puigserver et al., 1998), PGC-1 has since
been implicated in a variety of cellular processes, including
the metabolic responses to fasting (Lehman et al., 2000) and
exercise (Knutti and Kralli, 2001; Baar et al., 2002).
Central to PGC-1’s role in cellular physiology is its
ability to activate the transcription of genes involved in
mitochondrial respiration and biogenesis (Scarpulla,
2002). PGC-1 is a transcriptional coactivator, meaning
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that it facilitates the interactions of transcription factors
and their activating proteins to form functional DNA-
binding complexes. PGC-1 cannot bind DNA or activate
transcription alone, so its downstream effects are com-
pletely dependent on coexpressed transcription factors. To
regulate metabolic genes, PGC-1 interacts with nuclear
respiratory factor 1 (NRF-1) and the nuclear respiratory
factor 2 complex, composed of GA-binding protein  and 
subunits (GABP, ). Transient overexpression of PGC-1
in nonneuronal cells increases the expression of cyto-
chrome c oxidase subunits (Scarpulla, 2002), ATP syn-
thase  (Villena et al., 1998), and mitochondrial transcrip-
tion factor A, as well as uncoupling proteins (Tiraby et al.,
2003) and antioxidant enzymes (St-Pierre et al., 2003).
Several recent reports suggest that PGC-1 has critical
roles in neuronal function and signaling. Mice lacking the
gene for PGC-1 demonstrate progressive vacuolization in
various brain regions within the first 3 months of age and
exhibit abnormal behavioral characteristics (Lin et al.,
2004; Leone et al., 2005). In addition, PGC-1 expression
can be regulated by neuronal activity in vitro and in vivo
(Liang and Wong-Riley, 2006). From studies in nonneuro-
nal cells, it is clear that PGC-1 has the potential to
interact with a variety of transcription factors that influ-
ence neuronal signaling, plasticity, and survival. PGC-1
can coactivate estrogen and estrogen-related receptors
(Bramlett and Burris, 2002; Kressler et al., 2002; Schre-
iber et al., 2004), the thyroid hormone receptor (Zhang et
al., 2004), glucocorticoid receptors (Herzig et al., 2001;
Yoon et al., 2001), and members of the myocyte enhancing
factor 2 (MEF2) family (Czubryt et al., 2003). Of note, its
expression can be regulated by calcium/calmodulin-
dependent protein kinase II (CaMKII) and IV and cAMP-
responsive element binding protein (CREB; Herzig et al.,
2001; Yoon et al., 2001), and PGC-1 may play a role in
the physiological signaling of nitric oxide (Nisoli et al.,
2003).
To determine the possible causes for the observed phe-
notype in the knockout mice and the roles for PGC-1 in
brain development and function, we evaluated its tempo-
ral and cell-specific expression throughout forebrain and
cerebellar development in the rat. In addition, to identify
potential functions for PGC-1 in vivo, we investigated
whether PGC-1 was coexpressed with the chemoattrac-
tant reelin and the transcription factor myocyte enhanc-




For a comprehensive list of the antibodies and their
characteristics, see Table 1. Briefly, antibodies included
rabbit anti-PGC-1 (gift of Daniel P. Kelly, Center for
Cardiovascular Research, Washington University; Leh-
man et al., 2000), rabbit anti-MEF2, mouse anti--tubulin
III, mouse microtubule associated protein 2 (MAP2),
mouse anti-actin, mouse anti-NeuN, mouse anti-rodent
reelin, and mouse anti-glutamic acid decarboxylase (67 kD
isoform). The specificities of all antibodies were tested by
Western blotting (see procedure below). Staining patterns
from immunohistochemistry experiments were found to
be identical to those seen with immunofluorescence, and
the neuroanatomical and subcellular localization of immu-
noreactivity for all antibodies (except PGC-1) was simi-
lar to what has been previously reported.
ABBREVIATIONS
EGL External granule cell layer
IGL Internal granule cell layer
GABA -Aminobutyric acid
GAD67 Glutamic acid decarboxylase 67 (GAD1)
MEF2 Myocyte enhancing factor 2
ML Molecular cell layer
PGC-1 Peroxisome proliferator activated receptor  coactivator
1
PL Purkinje cell layer
TABLE 1. List of Antibodies
Target Host Antigen Dilution Specificity proven by Source/cat. #/lot #




Western blot (91 kD), overexpression,
nuclear localization
Custom from Quality Controlled
Biochemicals, Hopkinton,
MA; Animal #91378 Bleed #8
Actin Mouse a.a. 50-70 of chicken actin
(conserved)









Western blot (46 kD), nuclear
localization
Chemicon MAB377 25010730
TuJ1 (-tubulin) Mouse Microtubules from rat brain 1:5000 (WB)
1:2000
(IHC, IF)






protein 2A and 2B
Mouse Purified rat MAP2 1:200 (WB,
IHC, IF)
Western blot (280 and 300 kD),







a.a. 4-101 of human GAD67 1:4000 (WB)
1:2500
(IHC, IF)
Western blot (67 kD), in cytoplasm of




Reelin Mouse a.a. 164-496 of mouse reelin 1:500 (WB)
1:250 (IF)
Western blot (180, 300, and 400 kD),
cytoplasmic localization,












blot (64-70 kD; Allen et al., 2000),
nuclear localization, concentration
in cerebellum as previously
reported
Santa Cruz Biotechnology,
Santa Cruz, CA; Sc-313
D1405
a.a., amino acid; WB: Western blot; IHC: immunohistochemistry; IF: immunofluorescence; IP: immunoprecipitation.
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Tissue preparation
Animals were sacrificed at embryonic days (E)15, E18,
E21, postnatal days (P)3, P7, P14, P21, or 3 months of age
(adult). For embryonic timepoints, dams were euthanized
with sodium pentobarbital (100 mg/kg), pups were re-
moved, and brains were either frozen immediately for
RNA extraction, added to homogenization buffer for West-
ern blotting, or drop-fixed in 4% paraformaldehyde for
immunohistochemistry (see below). For isolation of post-
natal tissue for reverse-transcriptase polymerase chain
reaction (RT-PCR) and Western blotting, animals were
euthanized with sodium pentobarbital. For immunohisto-
chemistry, postnatal animals were anesthetized with a
mixture of ketamine (60 mg/kg) and xylazine (5 mg/kg)
and perfused intracardially with phosphate-buffered sa-
line (PBS, pH 7.4) and 4% paraformaldehyde in PBS. All
animal protocols were approved by the University of Mich-
igan and VA Medical Center centers for use of laboratory
animals.
Semiquantitative Western blot analysis
For animals ages E15–E21, whole brains were homog-
enized in RIPA buffer (150 mM NaCl, 1% Triton X-100,
0.5% sodium deoxycholate, 0.1% lauryl sulfate in 50 mM
Tris, pH 8.0) with 2% CHAPS (for the solubilization of
mitochondrial proteins) and protease inhibitors (Roche
Diagnostics, Indianapolis, IN). For ages P3–P21, single
hemispheres were used. For animals older than 21 days a
coronal block of tissue from one hemisphere (from approx-
imately bregma 1.0 through bregma 6.0) was isolated for
homogenization. Tissues were homogenized 30 strokes at
maximum speed with a Tissue Tearor (Research Products
International, Mount Prospect, IL) and centrifuged at
13,000 rpm for 30 minutes. The supernatant was frozen at
80°C until use or immediately mixed in sample buffer
(20% glycerol, 2% lauryl sulfate, 0.2 M dithiothreitol, and
0.3 mM bromophenol blue in 167 mM Tris, pH 6.8) and
boiled 5 minutes. Protein content was determined using
bovine serum albumin as a standard (Pierce Biotechnol-
ogy, Rockford, IL). To confirm that the centrifugation pro-
cess did not influence the isolation of PGC-1, another set
of forebrain samples (E21–P28; n  3/age group) was
collected, homogenized (100 mg/mL homogenization
buffer), and then boiled immediately in sodium dodecyl
sulfate (SDS) sample buffer without centrifugation. Pro-
teins were separated with SDS polyacrylamide gel elec-
trophoresis (PAGE) electrophoresis on 8% polyacrylamide
gels (10 g/lane; Invitrogen, Carlsbad, CA) and trans-
ferred to nitrocellulose membranes (Bio-Rad Laboratories,
Hercules, CA), and Western blotting was performed as
described by Cell Signaling Technology (Danvers, MA),
with slight modifications. Briefly, blocking was performed
for 1 hour with 5% dry milk in Tris-buffered saline (TBS;
0.15 M NaCl, 0.02 M Tris, pH 7.6), and the membrane was
incubated with the primary antibody in 5% IgG-free BSA
(Jackson Immunoresearch, West Grove, PA) overnight at
4°C and then with the peroxidase-conjugated secondary
antibody (Jackson Immunoresearch) in 5% milk for 1
hour. Signal was detected with enhanced chemilumines-
cence (Amersham Biosciences, Piscataway, NJ) and expo-
sure to Biomax Kodak film (Eastman Kodak, Rochester,
NY). Films were scanned and imported into ImageQuant
5.2 software for the estimation of band intensity. Three
developmental time courses (E15 to adult; eight animals
per set) were run on separate gels, and all values were
normalized to actin and then compared to the P3 value on
the same gel. Values are expressed as percent of the P3
value  standard error.
To generate a positive control for the PGC-1 Western,
we transfected SH-SY5Y neuroblastoma cells (MOI: 25:1)
with an adenovirus for mouse PGC-1 (generously pro-
vided by Bruce M. Spiegelman, Dana Farber Research
Institute and Harvard University; Lin et al., 2003) for 48
hours, collected the cells in RIPA buffer as above, and
processed the samples for PGC-1 Western blotting.
Quantitative RT-PCR
E18 to adult brains were removed and placed on ice for
the isolation of the hippocampus, cortex, striatum, thala-
mus, and cerebellum. Tissue pieces were collected in cen-
trifuge tubes and snap-frozen in liquid nitrogen. RNA was
isolated by the Trizol method following manufacturer’s
instructions (Invitrogen), with chloroform and isopropa-
nol, was washed in ethanol, and resuspended in RNAse-
free water. Equivalent amounts of RNA (2.5 g) were
treated with DNase I at 37°C for 30 minutes (1 unit DNase
per g RNA; Promega, Madison, WI), DNase was inacti-
vated at 65°C for 15 minutes, and RNA was reverse-
transcribed using the High-Capacity cDNA Archive Kit
(Applied Biosystems, Foster City, CA). Taqman PCR was
performed with mastermix (Applied Biosystems) and
primers for eukaryotic 18s rRNA or PGC-1 mRNA (Ap-
plied Biosystems; Cat. Nos. Hs99999901_s1 and
Rn00580241_m1, respectively). 18s has been used previ-
ously as a standard in brain development (Al-Bader and
Al-Sarraf, 2005), as 18s content is directly correlated with
total RNA content (Schmittgen and Zakrajsek, 2000). Re-
actions were run performed with an initial ramp time of 2
minutes at 50°C and 10 minutes at 95°C, and 40 subse-
quent cycles of 15 seconds at 95°C and 1 minute at 60°C.
As a negative control for the RT reaction, reverse tran-
scriptase was omitted in the reaction mix. For negative
controls for the PCR reaction, either the primer sets or the
cDNA were omitted from the reactions. Relative concen-
trations of PGC-1 or 18s RNA were calculated with com-
parison to a standard curve made with dilutions of cDNA
from E21 thalamus. Values for PGC-1 were normalized
to 18s values for the same samples; values are expressed
as arbitrary units (ratio of PGC-1 to 18s)  standard
error.
Immunohistochemistry
Brains were removed, postfixed in paraformaldehyde
for 24–72 hours at 4°C, cryoprotected in graded sucrose
solutions (5–20%), embedded 1:1 in 20% sucrose and OCT
media (VWR, West Chester, PA), and frozen at 80°C.
Tissue blocks were sectioned at 20 m, mounted on
charged slides (Fisher, Hampton, NH), and allowed to dry
overnight before freezing at 80°C until use. For immu-
nohistochemistry and immunofluorescence, slides were
thawed, rinsed 5 minutes, and blocked with 10% serum
from the host of the secondary antibody in PBS, pH 7.4. If
no antigen retrieval process was required (see below),
sections were incubated with the primary antibody over-
night in PBS with 0.3% Triton X-100 at 4°C. All optimal
dilutions for primary antibodies were determined with
and without the antigen retrieval step. After incubation
with the primary antibody, sections were washed, incu-
bated 1 hour with the corresponding secondary antibody,
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peroxidase-quenched with 0.3% hydrogen peroxide in
methanol, and incubated with the horseradish-
peroxidase-labeled ABC reagent (Vector Laboratories,
Burlingame, CA) for 30 minutes. After washing, antibody
binding was visualized with diaminobenzamide. Stained
sections were dehydrated in graded ethanols and xylenes
and mounted with nonaqueous mounting media. Selected
images were captured using a SPOT camera attached to a
Nikon Microphot-SA light microscope with 4, 10, 20,
and 60 objectives, and images were imported into Adobe
Photoshop 7.0 (San Jose, CA) for processing. Images were
adjusted for brightness, contrast, and sharpness.
To rule out nonspecific binding of the secondary anti-
body and autofluorescence, primary antibodies were re-
placed with species-matched nonspecific IgG.
Immunofluorescence and confocal
microscopy
For double- or triple-labeling immunofluorescence, sec-
tions were blocked with donkey serum and primary anti-
bodies from different species were pooled and applied to
sections overnight, as described above. Secondary antibod-
ies, all made in donkey, were pooled and applied to sec-
tions for 1 hour at room temperature. Immediately after
removal of the secondary antibodies, sections were incu-
bated with DAPI (150 ng/mL; Molecular Probes, Eugene,
OR) for 10 minutes for visualization of cell nuclei. After
washing, sections were coverslipped with antifade media
(Molecular Probes) and allowed to dry at room tempera-
ture overnight before storage at 4°C. Immunofluorescence
was visualized in triple channel mode on an Olympus
IX-71 inverted microscope (using a 20 air or 40 oil
objective) equipped with an Olympus FluoView 500 con-
focal laser scanning imaging system at the Michigan Di-
abetes Research and Training Center (University of Mich-
igan, Ann Arbor, MI). Data were collected from each
channel sequentially and barrier filters minimized chan-
nel leak-through (430–460 nm barrier filter in the DAPI
range and 505–525 nm barrier filter in the FITC range).
The images from two or three channels were merged and
the brightness and contrast of the images were adjusted
with Adobe Photoshop 7.0.
Antigen retrieval
For antigen retrieval (required for optimal staining of
-tubulin, MAP2, PGC-1, and GAD67), sections were
blocked with 10% serum in PBS, incubated in citrate
buffer (10 mM citric acid, pH 5.0) for 30 minutes at 37°C,
rinsed for 5 minutes in PBS, then incubated with the
primary antibody(ies) overnight, as above.
Statistical analysis
Western blotting and quantitative RT-PCR data were
expressed as mean  standard error. Significant differ-
ences among groups were determined using one-way anal-
ysis of variance (ANOVA). Post-hoc analyses to determine
significant differences between individual groups were
performed using a 2-tailed t-test, assuming unequal vari-
ances. Statistical significance was set at P  0.05.
RESULTS
Detection of PGC-1 by Western blot
In initial experiments, we used a PGC-1-specific anti-
body to detect PGC-1 in whole brain homogenates by
Western blotting (Fig. 1A). As expected, the antibody de-
tected a band of 91 kD; the signal was stronger in P3 brain
than in adult brain. The antibody also recognized overex-
pressed PGC-1 (FLAG-tagged; Lin et al., 2003) in the
neuroblastoma cell line SH-SY5Y at 	110 kD, indicating
that the antibody specificity was sufficient for Western
blot analysis.
To investigate changes in PGC-1 protein expression
throughout brain development, we performed Western
blots for PGC-1 on whole forebrain and whole cerebellum
homogenates from embryonic (E15, E18, E21) and postna-
tal (P3, P7, P14, P21, P90) animals (n  3/age group).
Three sets of developmental time courses were run on
separate gels and band intensity was estimated with nor-
malization to actin (run on the same gel). PGC-1 signal
declined progressively with age in the forebrain (Fig.
1B,C) in comparison to actin-. Signal for PGC-1 was
strong in animals age E15 to P14, low at P21, and unde-
tectable in adult brain homogenates. In the postnatal cer-
ebellum, PGC-1 signal was strong from P3–P21 and re-
duced, but still detectable, in the adult. While others have
reported that actin expression at the RNA level changes in
development, we did not see any influence of age on actin
protein expression. Values are expressed as percent of the
P3 value from the same gel. Results from each sample set
were consistent and demonstrated a decrease in PGC-1
with developmental age in the forebrain (P 
 0.01, one-
way ANOVA) and a significant decrease by adulthood in
the cerebellum (P 
 0.01, one-way ANOVA). To investi-
gate the possibility that a significant amount of PGC-1
was trapped in the pellet after centrifugation, we pro-
cessed a separate set of samples without centrifugation
and boiled the samples directly in SDS sample buffer.
While the signal for PGC-1 was slightly increased in the
older (P28) tissue samples, the overall trend was the
same. Intensity values (percent of one P3 value  SE) for
each age were as follows: E21, 201  57; P3, 133  23; P7,
102  42; P14, 43  23; P21, 50  19; P28, 28  19.
PGC-1 expression differed among age groups (n  3/age
group; P 
 0.01; one-way ANOVA) and decreased signifi-
cantly between P3 and P14 (P 
 0.03; t-test).
Regional analysis of PGC-1 mRNA
expression by quantitative RT-PCR
While the Western blot results indicated that PGC-1
protein was more abundant during prenatal brain devel-
opment than postnatal development, these data were lim-
ited by the fact that Western blot is often insensitive
(PGC-1 could be expressed in adult animals even though
there was little signal) and that Western results from
whole brain homogenates give no indication of neuroana-
tomical distribution. To evaluate region-specific changes
in PGC-1 expression, we isolated four brain regions re-
ported to be most affected in the knockout animals (stri-
atum, hippocampus, cortex, and thalamus) and one area
that was only mildly affected (cerebellum) from animals of
different ages, using 18s rRNA as an internal standard
(see Materials and Methods). 18s RNA signal (arbitrary
units  SE) remained constant with age in all regions (i.e.,
thalamus: E21, 0.85  0.08; P3, 0.89  0.07; P7, 0.86 
0.04; P14, 0.89  0.07; P21, 0.85  0.04; adult, 0.84 
0.08; n  4–5/age group; P  0.99, one-way ANOVA).
PGC-1 mRNA expression profiles differed markedly from
region to region, and substantial mRNA expression was de-
tected in adult brain in all regions tested (Fig. 2). Of the five
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regions evaluated, thalamus was the only region that
showed no measurable change in PGC-1 mRNA expression
with age (n  3–6/age group; P  0.36; one-way ANOVA). In
the other four regions (striatum, cortex, hippocampus, and
cerebellum), mRNA expression changed significantly with
developmental age (n  3–6/age group; P 
 0.01 for all;
one-way ANOVA). Post-hoc statistical analysis (t-test, two-
sample assuming unequal variances) revealed that PGC-1
expression in the P7 striatum was significantly greater than
in the P3 striatum (P  0.02) and that RNA expression
decreased in the adult with respect to P14 animals (P 
0.05). In the cortex, a marked increase in RNA expression
was observed between P7 and P14 (P 
 0.01), but there was
not a significant difference between P14 and adult values
(P  0.1). PGC-1 expression in the hippocampus looked
similar to that in the striatum, with an increase detected
between P7 and P14 (P  0.03), and expression was de-
creased significantly in the adult in comparison to P14 hip-
pocampus (P  0.04). In contrast, in the cerebellum, expres-
sion at P14 was significantly lower than expression at P3
(P  0.02).
Comparison among regions of P3, P14, and adult brain
(Fig. 2F) indicated that PGC-1 expression varied by re-
gion (P3: P 
 0.01; P14, adult: P 0.01; one-way ANOVA).
Of note, the cortex expressed the least amount of PGC-1
at P3 (P 
 0.01; t-test) and the cerebellum expressed more
PGC-1 than the striatum (P  0.04) or hippocampus (P 
0.05) in adults.
Regional analysis of PGC-1 expression
with immunohistochemistry and light
microscopy
One report has indicated that PGC-1 RNA is expressed
throughout the mouse brain (Tritos et al., 2003), but its
cellular localization in development and adulthood in the
rat is unknown. To determine the regional and cell-
specific expression of PGC-1 during brain development,
we used immunohistochemistry and immunofluorescence
with the antibody proven to be specific for PGC-1 by
Western blot (Fig. 1). Initial immunohistochemical assays
showed very little specific staining; because the antibody
worked well for Western blotting, we hypothesized that an
antigen retrieval step was required (citrate buffer prein-
cubation, see Materials and Methods). With this proce-
dure, widespread PGC-1 immunoreactivity was observed
throughout the brain at all ages tested. To allow compar-
ison of intensity across ages, sections from each develop-
mental age were included in all experiments. At low mag-
nification, it was clear that the intensity of staining in
gray matter correlated well with the Western blotting
results; with increasing age, the overall intensity of stain-
ing decreased. However, at higher magnification, it was
evident that staining in embryonic brain was not concen-
trated highly within cell bodies, but diffuse throughout
the forming cortical plate and in gray matter areas. Inter-
Fig. 1. The abundance of PGC-1 protein decreases during fore-
brain and cerebellar development. Using an antibody specific for
PGC-1, PGC-1 protein was detected in whole forebrain and cere-
bellum homogenates from embryonic and postnatal rats. A: Native
PGC-1 (91 kD) is detectable in P3 forebrain. The antibody recognizes
both native and FLAG-tagged PGC-1 (	110 kD), overexpressed with
an adenovirus in the SH-SY5Y neuroblastoma cell line (AdV). In this
film no PGC-1 was detectable in the adult (A) forebrain sample.
B: PGC-1 protein is detectable from E15 through P14 forebrain but
not in P21 or adult samples; the intensity of the band decreases with
developmental age. C: Relative intensity of the PGC-1 band was
measured (see Materials and Methods), with reference to the P3
sample on the same gel, and normalized to the intensity of the actin
band. The intensity of the PGC-1 band decreases significantly with
age (P 
 0.01, n  3/age group). D: PGC-1 protein was detected in
cerebellar homogenates from postnatal rat brain; similar to the re-
sults seen for forebrain samples, the intensity of the band was more
pronounced in younger animals. E: The intensity of the PGC-1 and
actin bands were quantified, and values are expressed as a percent of
the intensity of the P3 sample on the same gel. The signal intensity of
adult samples was significantly decreased with respect to samples
from younger animals (P 
 0.01; n  3/age group).
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Figure 2
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estingly, at later ages (P7 to adulthood), immunoreactivity
was found specifically in cell bodies, and less in processes.
Cortex. In coronal sections of E15 brain, PGC-1 im-
munoreactivity was widespread, but most concentrated in
the forming cortical plate (CP, Fig. 3A,E). To determine
the correlation between the appearance of PGC-1 immu-
noreactivity and the appearance of neurons in the embry-
onic brain, we compared PGC-1 immunoreactivity to
NeuN, MAP2, and -tubulin immunoreactivity (Fig. 3A–
F). The pattern of PGC-1 immunoreactivity corre-
sponded most closely with immunoreactivity for NeuN
and MAP2; only faint staining for PGC-1 was detectable
in the -tubulin-positive intermediate zone.
PGC-1 was also localized to the cortical plate at E18
(Fig. 3G–J) and E21 (not shown). While PGC-1 immuno-
reactivity was faint in the cortical subplate (SP; Fig. 3G,I),
it was concentrated in regions of NeuN immunoreactivity
(Fig. 3H,J). PGC-1 immunoreactivity was present at the
same location and developmental stages as NeuN immu-
noreactivity in all regions evaluated.
In early postnatal cortex (P3), PGC-1 immunoreactiv-
ity (Fig. 3K) was widespread in areas of NeuN immuno-
reactivity (Fig. 3L). However, in contrast to E18 and E21
cortex, distinct PGC-1 staining was found in individual
cell bodies (Fig. 3K, arrowheads). At P7 (not shown) and
P14 (Fig. 3M,N), more darkly stained cell bodies were
observed (Fig. 3M, arrowheads) as the density of NeuN-
stained cells decreased (Fig. 3N). In adulthood (P90), all
PGC-1-specific staining was localized to cell bodies (Fig.
3O). Of note, there were fewer PGC-1-positive cells than
NeuN-positive cells (Fig. 3P) in the adult cortex. With
respect to laminar organization, the greatest number of
PGC-1-positive cells were noted in Layers II and III of
the cortex, where the staining for glutamic acid decarbox-
ylase 67 (GAD67) was the most intense (Fig. 3Q). In Lay-
ers II/III (Fig. 3R) and IV (Fig. 3S), small cells were
immunoreactive for PGC-1 (arrowhead), while larger
cells displayed only faint staining (Fig. 3S, arrows). Little
staining could be attributed to the secondary antibody
alone (primary antibody replaced with nonspecific rabbit
IgG; Fig. 3T).
Hippocampus. Staining for PGC-1 was present in
areas of NeuN immunoreactivity in the embryonic hip-
pocampus at E18 and E21 (not shown). In P3 and all older
animals, faint cellular immunoreactivity for PGC-1 was
noted in all regions with NeuN immunoreactivity, with
concentrated staining in few cells. Representative images
are shown from the adult hippocampus (Fig. 4). At low
magnification, PGC-1 immunoreactivity was visible
throughout the pyramidal cell layer (CA1, CA3 regions),
subiculum, and dentate gyrus (Fig. 4A), with few scat-
tered immunoreactive cells outside these neuronal layers.
At higher magnification, faint PGC-1 immunoreactivity
was noted in cells of the dentate gyrus (Fig. 4B,D) in a
pattern similar to NeuN (Fig. 4C,E), with few being in-
tensely immunoreactive for PGC-1 (Fig. 4B, arrowhead;
Fig. 4D). Just adjacent to the dentate gyrus, large PGC-
1-positive cells were noted (Fig. 4F,H) with a staining
pattern similar to NeuN (Fig. 4G,I). This was the case for
other regions of the hippocampus as well, including the
CA3 region of the pyramidal cell layer.
Striatum. Due to the possible role of PGC-1 in stri-
atal function (Lin et al., 2004), we also investigated the
distribution of PGC-1 immunoreactivity in the striatum
(Fig. 4J–M). Most cells demonstrated little to no specific
staining, while a small percentage of cells were intensely
immunoreactive for PGC-1 (Fig. 4J,L). PGC-1-positive
cells were in the same location and had the morphology of
NeuN-positive neurons (Fig. 4K,M).
Cerebellum. Immunohistochemistry for PGC-1 in
sagittal sections of cerebellum indicated that PGC-1 was
concentrated in multiple neuronal populations in the de-
veloping and adult cerebellum. At P3, when Purkinje cells
were aligning to form the Purkinje cell layer (PL), they
were intensely immunoreactive for PGC-1 (Fig. 5A,B).
Little staining was seen in the external granule cell layer
(EGL; Fig. 5B). Neurons of the cerebellar deep nuclei were
also PGC-1-positive (Fig. 5A,C). In the adult cerebellum
(Fig. 5D–F), the granule cells had migrated into the inter-
nal granule cell layer (IGL), and the Purkinje cells had
formed a monolayer (Fig. 5D). Purkinje cells (arrowheads,
Fig. 5D,E), cells in the IGL, and scattered cells in the
molecular cell layer (ML; arrows, Fig. 5D,E) were PGC-
1-immunoreactive, as were neurons in the deep cerebel-
lar nuclei (Fig. 5F). The pattern of PGC-1 immunoreac-
tivity in the ML and deep nuclei was similar to that
observed for NeuN and -tubulin (not shown).
PGC-1 and GABA. More thorough analysis of
PGC-1 immunoreactivity patterns throughout the devel-
oping brain revealed an interesting pattern. PGC-1 was
most concentrated in regions with neurons that produce
the neurotransmitter -aminobutyric acid (GABA), and
the cellular distribution of PGC-1-positive cells in the
cortex, hippocampus, and cerebellum mirrored the distri-
bution of GABAergic neurons in those regions. As an ex-
ample, images from one GABAergic region, the globus
pallidus (GP), are presented (Fig. 5G–J). At P3, the neu-
rons within the globus pallidus were densely populated
and strongly immunoreactive for PGC-1 (Fig. 5G,H). In
contrast, few cells within the neighboring striatum (Str)
were PGC-1-positive (Fig. 5G). Globus pallidus neurons
in the adult brain were also strongly positive for PGC-1
Fig. 2. Analysis of PGC-1 mRNA expression in the thalamus,
striatum, cortex, hippocampus, and cerebellum. To determine if
PGC-1 expression varied by region in the developing rat brain, five
brain areas (thalamus, striatum, cortex, hippocampus, and cerebel-
lum) were dissected and processed for quantitative RT-PCR for
PGC-1 (n  3-6/age group). The signal from each sample was nor-
malized to the same sample’s 18s rRNA content. To allow comparisons
among all samples tested, the same standards were used for every
PCR reaction. Values are expressed as arbitrary units  standard
error, after normalization to 18s rRNA content. P values for post-hoc
t-tests are labeled on each graph. A: PGC-1 mRNA expression was
detectable in thalamus at all ages tested; expression did not change
with developmental age (P  0.36). B: PGC-1 mRNA expression
changed significantly with age in striatum (P 
 0.01, one-way
ANOVA), with a significant increase occurring between P3 and P7
and a decrease between P14 and adult. C: In the cortex, PGC-1
expression significantly differed among age groups (P 
 0.01); expres-
sion increased significantly between P7 and P14, but did not decrease
appreciably by adulthood. D: PGC-1 expression differed among sam-
ples (P 
 0.01) in the hippocampus. Significant increases were de-
tected between E21–P3 and P7–P14, and expression decreased be-
tween P14 and adult. E: In the cerebellum, PGC-1 mRNA was
abundant at all ages and changed significantly with age (P 
 0.01).
F: To visualize region-specific changes in PGC-1 mRNA expression
by age, the same data displayed in A–E is grouped by age. In early
postnatal rat brain (P3), expression is lowest in the cortex. In P14 and
adult samples, expression is widespread.
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(Fig. 5I,J), although the density of PGC-1-positive neu-
rons was reduced at this age.
GABAergic thalamic nuclei such as the reticular nucleus
of the thalamus also exhibited very intense PGC-1 immu-
noreactivity. Other regions that contained PGC-1 immuno-
reactive cell bodies, but that are not described in further
detail here, include the olfactory bulb, hypothalamus, ves-
tibular nucleus, brain stem reticular nuclei, red nucleus,
nucleus of the solitary tract, trapezoid body and inferior
olive, mammillary nucleus, habenula, piriform cortex, amyg-
dala, and the lateral dorsal and ventrolateral nuclei of the
thalamus. There was little staining in medial thalamic nu-
clei, mammillary bodies, or the deep pontine gray.
Cell-specific localization of PGC-1 with
immunofluorescence and confocal
microscopy
To localize PGC-1 to specific cell types in the develop-
ing brain, we used immunofluorescence and confocal mi-
croscopy. At P3 and earlier, PGC-1 immunoreactivity
was not distinctively localized to cell bodies but was dif-
fusely distributed throughout NeuN-positive areas (Fig.
3G–J,M,N). This diffuse pattern was confirmed with con-
focal microscopy (Fig. 6A). At P7, however, immunoreac-
tivity was more concentrated in cell bodies (arrowheads,
Fig. 6B) that were NeuN-positive (Fig. 6B2,B3). Faint
staining was still observed in other cells, but was always
associated with NeuN (arrows, Fig. 6B). At P14 a similar
pattern was seen, with PGC-1 being concentrated in a
low percentage of NeuN-positive cells. In most cases,
PGC-1-positive cells were small in comparison to neigh-
boring cells (arrows, Fig. 6C). Notably, during this tran-
sition from diffuse homogeneous staining to cell-specific
staining, cell size increased markedly (Fig. 6A,B, and C at
same magnification). Also, thorough analysis of NeuN and
PGC-1 colocalization indicated that PGC-1 immunore-
activity was rarely present in the absence of NeuN;
PGC-1 immunoreactivity was consistently absent
throughout development in white matter regions and ar-
eas of physiologically activated microglia (P7 and earlier).
PGC-1 also colocalized with -tubulin (see Fig. 6P) and
MAP2 (not shown).
From the results with immunohistochemistry, we hypoth-
esized that PGC-1 was present in GABAergic neurons. To
test this idea, we investigated whether PGC-1 colocalized
with the protein GAD67, one of two enzymes responsible for
the conversion of glutamate to GABA (Kaufman et al., 1991).
With the citrate buffer pretreatment, GAD67 immunoreac-
tivity was detectable in the cytoplasm of cells as well as in
cellular processes (green, Fig. 6D–H). Because many cells
exhibited GAD67-positive synaptic contacts (arrows, Fig.
6E2), we classified GABAergic neurons by their cytoplasmic
staining. Remarkably, most GAD67-positive neurons identi-
fied throughout the brain were immunoreactive for PGC-1
(red, Fig. 6D–H). In the P14 cortex, many PGC-1-positive,
GAD67-positive neurons were identified (arrowheads, Fig.
6D) in the vicinity of GAD67-negative cells with little
PGC-1 immunoreactivity (arrows, Fig. 6D). In the adult
cortex, GAD67-positivity was more intense; cytoplasmic
staining was distinct in the cytoplasm of PGC-1-positive
cells (arrowheads, Fig. 6E), while little PGC-1 immunore-
activity was detectable on cells with only cell-surface GAD67
(arrows, Fig. 6E). At high magnification it was evident that
PGC-1 localized mainly to the nucleus of GAD67-positive
neurons (arrowhead, Fig. 6F) with faint staining in the cy-
toplasm. No PGC-1 was detectable in cellular processes
(arrows, Fig. 6F).
In the pyramidal cell layer of the hippocampus at P14,
PGC-1 immunoreactivity was concentrated in GAD67-
positive neurons (Fig. 6G); faint PGC-1 immunoreactiv-
ity was present in GAD67-negative cells. At all postnatal
ages studied, PGC-1 immunoreactivity was also localized
to GAD67-positive cells throughout the striatum (Fig. 6H),
with GAD67-negative cells showing no positivity for PGC-
1. In other areas, including the globus pallidus, reticular
nucleus of the thalamus, olfactory bulb, superior and in-
ferior colliculus, and hypothalamus (not shown), PGC-1
also colocalized with GAD67.
In the developing and mature cerebellum, PGC-1 im-
munoreactivity was localized to several cell types, includ-
ing Purkinje cells and molecular layer (ML) interneurons
(Fig. 7). At P14, PGC-1 was most concentrated in the cell
bodies and apical processes of Purkinje cells (arrowheads,
Fig. 7A). Cells were still present in the EGL; these were
not immunoreactive for PGC-1 (Fig. 7A1). Molecular
layer interneurons near the Purkinje cell layer (PL; ar-
rows; Fig. 7A2) were also reactive for PGC-1. At this
stage GAD67 was detectable in Purkinje cell bodies and
processes and in some ML interneurons. At P21, the EGL
was no longer present, interneurons were more dispersed
throughout the ML, and PGC-1 immunoreactivity was
concentrated in Purkinje cells (arrowhead; Fig. 7B) and
ML interneurons (arrows; Fig. 7B). At this age, GAD67
immunoreactivity was visible throughout the ML and co-
localization of PGC-1 and GAD67 was evident (Fig. 7B4).
Regarding the expression of PGC-1 in the internal gran-
Fig. 3. The distribution of PGC-1 immunoreactivity parallels
that of the neuronal marker NeuN during late embryonic develop-
ment and localizes to specific cell populations during postnatal corti-
cal development. To investigate the neuroanatomical and cell-specific
expression of PGC-1, the PGC-1-specific antibody (used for Western
blotting; see Fig. 1) was used to detect PGC-1 in brain sections from
rats of different developmental ages. A–F: Low-magnification images
of coronal sections of the E15 rat brain demonstrate that PGC-1 (A)
is most concentrated in regions of NeuN and MAP2 immunoreactivity
(B,C, respectively; the forming cortical plate), but diffuse in the
tubulin-positive intermediate zone (D). At higher magnification it is
evident that the immunoreactivity for PGC-1 (E) is concentrated in
the cortical plate (CP), similar to NeuN (F), but faint in the cortical
neuroepithelium (NE). G–J: Immunostaining for PGC-1 and NeuN
in sagittal sections of E18 brain reveal that the cortical plate is
thicker and remains immunoreactive for PGC-1 (G,I) and NeuN
(H,J). K,L: In the P3 cortex (sagittal plane), most PGC-1 immuno-
staining (K) is faint and diffuse, except for a band of cells that shows
intense staining (arrowheads). The diffuse staining is in the vicinity of
many NeuN-labeled neurons (L). M,N: In the P14 cortex, more in-
tensely labeled cells (arrowheads) are noted throughout all cortical
layers. O–Q: In the adult cortex (sagittal plane), PGC-1 immunore-
activity is mainly cellular, and PGC-1-labeled cells (O) are less
abundant than NeuN-labeled cells (P). Neuronal packing density
(higher in Layers IV and VI) and immunoreactivity for glutamic acid
decarboxylase 67 (GAD67; Q) allows for identification of cortical lay-
ers. In Layers II/III (R), a higher proportion of cells show intense
immunoreactivity for PGC-1 (arrowheads), than in Layer IV (S). In
all layers, PGC-1-immunoreactive cell bodies were small in compar-
ison to faintly stained neurons (arrows). Specificity of staining was
confirmed by processing serial sections with rabbit IgG in place of the
primary antibody; little immunoreactivity was seen in sections incu-
bated with rabbit IgG (T). CP, cortical plate; NE, cortical neuroepi-
thelium; SP, cortical subplate. Scale bars  300 m in A–D; E, 100 m
in F,I,J; 200 m in G,H; 150 m in K–N; 75 m in O–Q; 50 m in R–T.
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ule cell layer (IGL), immunoreactivity was detectable in
the IGL in thick sections with light microscopy (see Fig.
5D,E), but in confocal sections it was evident that these
cells had the least immunoreactivity of any other cells.
Other cells that were GAD67-negative such as cells with
the morphology of descending granule cells (black arrow-
heads, Fig. 7B) were not immunoreactive for PGC-1.
To confirm that the staining for PGC-1 in the ML was
in neurons, we used an antibody for -tubulin to label
neurons and Purkinje cells (Fig. 7C). Most PGC-1-
positive cells in the ML (arrows, Fig. 7C) were immuno-
reactive for -tubulin (Fig. 7C3).
Colocalization of PGC-1 with reelin and
MEF2
To identify possible functions for PGC-1 during devel-
opment, we tested whether PGC-1 was present in a spe-
cific subpopulation of GABAergic neurons, in particular,
neurons that expressed the chemoattractant reelin. This
neuronal population is compromised in neurodevelopmen-
Fig. 4. PGC-1 immunoreactivity is concentrated in specific neu-
rons in the adult hippocampus and striatum. Sagittal sections of adult
rat hippocampus and striatum indicate that PGC-1 is most intense
in a small number of cells and faint in the majority of other neurons.
A: At low magnification, faint staining is visible throughout the sub-
iculum (Sub), pyramidal cell layer (CA1 and CA3), and dentate gyrus
(DG) of the adult hippocampus. Areas pictured at higher magnifica-
tion are boxed and lettered accordingly. B–E: In the dentate gyrus,
faint PGC-1 immunoreactivity (B,D) is observed in most cells in the
same location as NeuN-positive neurons (C,E), but one cell shows
intense staining (arrowhead, B,D). F–I: In the middle of the dentate
gyrus, large cells (arrowheads) have a pattern of PGC-1 immunore-
activity (F,H) similar to that for NeuN (G,I), suggesting that PGC-1
is localized to the nucleus of these cells. J–M: PGC-1 immunoreac-
tivity is detectable in scattered cells in the striatum as well (J,L); only
few cells in the area of NeuN-labeled cells (K,M) show intense immu-
noreactivity (arrowheads, J; pictured in L). Sub, subiculum; CA1,
CA3, cornu ammonis, regions 1 and 3; Sul, hippocampal sulcus; DG,
dentate gyrus. Scale bars  500 m in A; 100 m in B,C,F,G,J,K; 40
m in D,E,H,I,L,M.
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tal disorders such as autism and schizophrenia (Costa et
al., 2001; Fatemi, 2005). We found that PGC-1 colocal-
ized with reelin in the cortex and hippocampus from P3 to
adulthood (for adult cortex, see Fig. 8A). At all ages reelin
was primarily cytoplasmic. Interestingly, both PGC-1-
positive (arrowheads, Fig. 8A) and PGC-1-negative
reelin-positive cells (arrows; Fig. 8A) were identified. Al-
though we were unable to determine whether these reelin-
positive PGC-1-negative neurons were GAD67-negative
(because both GAD67 and reelin antibodies were made in
mouse), from the literature it is known that 	30% of
reelin-positive neurons in the cortex are GAD67-negative,
Fig. 5. PGC-1 is expressed abundantly in the cerebellum and
globus pallidus in the developing brain. A–C: In sagittal sections of
the P3 cerebellum, PGC-1 immunoreactivity is visible in the forming
Purkinje cell layer (PL; A,B) and the deep nucleus (DN; A,C). Only
faint staining is seen in the external granule cell layer (EGL; B).
D–F: In a sagittal section of the adult cerebellum, PGC-1 immuno-
reactivity is visible on cell bodies in all cell layers, being the most
concentrated in Purkinje cells (arrowheads) and molecular layer in-
terneurons (basket and stellate cells; arrows). Immunoreactivity is
also visible on granule cells in the internal granule cell layer (IGL). At
this age, neurons of the deep nucleus are also immunoreactive (F).
G,H: In sagittal sections of P3 forebrain, intense PGC-1 immunore-
activity is found in the globus pallidus (GP). This is in stark contrast
to the neighboring striatum (Str), which has only a few scattered
PGC-1-positive cells (see Fig. 4J). I,J: PGC-1-positive cells are also
found in the adult globus pallidus, but the density of immunoreactive
cells is markedly reduced (G and I are at the same magnification). DN,
deep nucleus of the cerebellum; EGL, external granule cell layer; PL,
Purkinje cell layer; ML, molecular cell layer; IGL, internal granule
cell layer; GP, globus pallidus; Str, striatum. Scale bars  500 m in
A; 50 m in B,C,E,F,H,J; 100 m in D; 200 m in G,I.
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Figure 6
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and 	50% of GABAergic neurons do not express reelin
(Pesold et al., 1998). Because all GAD67-positive cells
observed in the cortex (P14 and older) expressed PGC-1,
we estimate that at least 50% of PGC-1-positive cells are
reelin-positive in older animals. While PGC-1 colocalized
with reelin in the forming cortical plate at E15, PGC-1
did not colocalize with reelin in the distinct band of reelin-
positive cells in Layer I during late embryonic and early
postnatal development (not shown).
To begin to identify some of the possible factors that can
interact with PGC-1 in GABAergic neurons, we deter-
mined whether the transcription factor MEF2 was ex-
pressed in the same cells as PGC-1. As expected from
previous reports (Lyons et al., 1995), we observed a par-
ticular concentration of MEF2 immunoreactivity in the
cerebellum (Fig. 8B) in Purkinje cells, ML interneurons,
and granule cells. However, we also noted that GAD67-
positive neurons in the striatum were intensely immuno-
reactive for MEF2 (Fig. 8C).
DISCUSSION
Neuronal PGC-1 expression in brain
development
Previous studies have shown that mice lacking PGC-1
exhibit neurological abnormalities and vacuolization in
various brain regions (Lin et al., 2004; Leone et al., 2005).
Interestingly, knockout animals die between birth and 3
weeks of life (50% mortality rate), suggesting that PGC-1
may be developmentally regulated (Lin et al., 2004). In
fact, PGC-1 is developmentally regulated in the heart
(Lehman and Kelly, 2002), and ectopic expression causes
cardiac hypertrophy and mitochondrial proliferation (Rus-
sell et al., 2004). Little is known about PGC-1 expression
in the brain and whether PGC-1 is expressed during
critical periods of brain development, so we used several
different methods to evaluate the temporal, regional, and
cell-specific expression of PGC-1 in the developing brain.
We found that PGC-1 is expressed by neurons through-
out the embryonic forebrain and primarily by GABAergic
neurons in the early postnatal and adult forebrain and
cerebellum. In addition, we determined that PGC-1
mRNA expression peaked at P14 in regions affected in the
knockout animals, a time of substantial metabolic changes
and synaptic remodeling.
Initially, the Western blot and RT-PCR results seemed
discordant; PGC-1 protein expression decreased with
age, while mRNA expression was low in embryonic brain
and high in early postnatal and mature brain. The West-
ern blot data indicate that PGC-1 constitutes a higher
percentage of total protein at earlier ages. This is clearly
demonstrated by the immunohistochemistry data showing
a decrease in the density of PGC-1-expressing cells with
developmental age (Fig. 5G–J) and the developmental
change in location of PGC-1 from widely cytosolic in all
neurons to nuclear in GABAergic neurons. The temporal
expression of mRNA, however, more closely follows the
observation of PGC-1 immunoreactivity in GAD67-
positive cells. It is possible that older GABAergic cells
have a higher rate of PGC-1 transcription than most
early neurons or that younger neurons have a higher rate
of protein translation or protein stability. We hypothesize
that PGC-1 protein is abundant throughout neuronal cell
processes and bodies until P7–P14, at which stage PGC-1
is localized mainly to the nucleus of GABAergic neurons to
act as a nuclear transcriptional coactivator. Currently, it
is not known whether PGC-1 has any physiological role
outside the nucleus. With the limited resolution of the
microscopy in samples from embryonic brain, it was im-
possible to localize extranuclear PGC-1 with any specific
organelle.
With immunohistochemistry and immunofluorescence,
we failed to detect any PGC-1 in corpus callosum and
other white matter tracts, and PGC-1 always colocalized
with the neuronal markers NeuN, MAP2, or tubulin.
While these results suggest that neurons are the primary
source of PGC-1 in the postnatal brain, it is possible that
glia express PGC-1 to a lower extent, not detectable by
immunohistochemistry and immunofluorescence. Prelim-
inary results from our laboratory suggest that Schwann
cells in culture can express PGC-1 when differentiated
using adenyl cyclase activators (unpubl. obs., R.M.C.); fur-
ther experiments are needed to determine whether glia
express PGC-1 during differentiation in vivo.
PGC-1, metabolism, and synaptic plasticity
The critical finding in this study is the specific localiza-
tion of PGC-1 to the nucleus in GABAergic neurons dur-
ing the first 3 weeks of life. During this particular phase of
brain development, a variety of critical processes are oc-
curring, including a change in mitochondrial dynamics
and the initiation of synaptogenesis. Specifically, between
P10 and P13 in the rat cortex there is a burst in mitochon-
drial protein synthesis (Polosa and Attardi, 1991) that
corresponds with a sharp increase in cytochrome c oxidase
activity, and cytochrome c oxidase IV expression (Cannino
et al., 2004). Concurrently, there is a rapid increase in the
number of synapses and synaptic vesicles (Jones and
Cullen, 1979; Blue and Parnavelas, 1983), oxidative me-
Fig. 6. PGC-1 immunoreactivity colocalizes with the neuronal
marker NeuN and glutamic acid decarboxylase (GAD67) in various
brain regions throughout development. Postnatal brain tissue was
sectioned in the sagittal plane and processed for immunofluorescence
and three-color confocal microscopy, using antibodies for PGC-1
(red), NeuN (as a neuronal marker; green), or GAD67 (to identify
GABAergic neurons; green). A DAPI counterstain was used to visu-
alize cell nuclei (blue). A–C: Immunostained sections through the
sensory-motor cortex of P3 (A), P7 (B), and P14 (C) brain reveal that
PGC-1 immunoreactivity (A1,B1,C1) is diffuse throughout the cortex
at P3 but concentrated in cell bodies at P7 and P14 (arrowheads).
When the PGC-1 and NeuN images are overlaid (A3,B3,C3), it is
evident that the cellular PGC-1 signal colocalizes with NeuN (ar-
rowheads). At P7 and P14, faint immunoreactivity is visible in other
NeuN-positive cells as well (arrows). D: At P14 in the cortex, PGC-1
(D1) is concentrated in cells that show intracellular GAD67 immuno-
reactivity (arrowheads; D2,D3); GAD67-reactive processes are visible
throughout the cortex. Faint immunoreactivity is observed in GAD67-
neagtive cells (arrows). E: In the adult cortex, PGC-1 (E1) is concen-
trated in GAD67-positive neurons (arrowhead, E2) and faint in neu-
rons that lack cytosolic GAD67 (arrows, E2,E4). In GAD67-positive
neurons, PGC-1 colocalizes with DAPI (E3,E4), indicating its pres-
ence in the nucleus. F: A high-power image of a cortical interneuron
demonstrates that PGC-1 (F1) is concentrated mostly in the DAPI-
positive nucleus (F3) of GAD67-positive neurons (F2,F4; arrowhead),
but that there is also faint immunoreactivity in the cytoplasm. Little
PGC-1 is found in neuronal processes in the adult (arrows). G: In the
hippocampus at P14, PGC-1 (G1) is localized to GAD67-positive
neurons (arrowheads, G2) in the pyramidal cell layer (G3). H: In the
adult striatum, PGC-1 (H1) is concentrated in GAD67-positive cells
(H2,H3). No PGC-1 is detectable in GAD67-negative cells. Scale
bars  50 m in A–D; 20 m in E,F; 40 m in G,H.
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tabolism, and mitochondrial number (Milstein et al.,
1968). Of note, these metabolic characteristics are similar
to those reported for the brainstem at earlier ages (P3; Liu
and Wong-Riley, 2003); the differences in critical meta-
bolic periods in the cortex and brainstem are likely reflec-
tive of the caudal-to-rostral development of this system. In
fact, PGC-1 immunoreactivity appeared in subcortical
structures earlier in development than in cortical struc-
tures.
Dendritic mitochondrial dynamics are very important in
synaptic plasticity. Increasing mitochondrial activity
and/or content has recently been shown to increase syn-
apse density (Li et al., 2004), and mitochondrial proteins
are highly expressed at times of plasticity in the develop-
ing visual cortex (Yang et al., 2001). Through interactions
with the transcription factors NRF-1 and GABP, PGC-1
can upregulate respiratory proteins including cytochrome
c oxidase, cytochrome c, and ATP synthase (Scarpulla,
2002). The developmental upregulation of PGC-1 could
play a role in the increase in mitochondrial activity and
number during this time as well as regulating metabolic
responses to neuronal activity. Notably, neuronal activity
Fig. 7. PGC-1 is expressed in multiple neuronal populations in
the developing cerebellum. A,B: At all ages tested, PGC-1 immuno-
reactivity was found in neurons of the cerebellum. Staining with
DAPI reveals the cellular layers of the cerebellum at P14 (A1) and P21
(B1). No PGC-1 staining (A2) is visible in the external granule cell
layer (EGL) at P14. Instead, PGC-1 is concentrated in GAD67-
positive Purkinje cells (A3,A4, arrowheads) and some cell bodies in
the lower molecular layer (ML; arrows, A3,A4). PGC-1 staining is
faint in the internal granule cell layer (IGL). At P21, no cells remain
in the EGL, and no PGC-1 immunoreactivity is detectable on
spindle-shaped cells migrating through the ML (black arrows; B1,B2).
PGC-1 and GAD67-immunoreactive cells are scattered in the ML
(arrow, B2–B4). Purkinje cells express PGC-1 at this age as well
(arrowhead, B3,B4). C: In the adult cerebellum, PGC-1 (C1) remains
concentrated in -tubulin-positive Purkinje cells (arrowheads, C2)
and cells scattered throughout the ML (arrows). Cells with intense
PGC-1 immunoreactivity also show -tubulin reactivity. EGL, exter-
nal granule cell layer; ML, molecular cell layer; PL, Purkinje cell
layer; IGL, internal granule cell layer. Scale bars  100 m.
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Fig. 8. The chemoattractant reelin and the PGC-1-binding tran-
scription factor MEF2 are localized to PGC-1-expressing neurons.
Sagittal sections from adult cortex (A) and P21 cerebellum (B) and
striatum (C) were processed for immunofluorescence and confocal
microscopy with antibodies for PGC-1, reelin, GAD67, and MEF2. A:
In the adult cortex, PGC-1 immunoreactivity (A1) colocalizes with
reelin in some cells (arrowheads), but not others (arrows). B,C: Im-
munoreactivity for the transcription factor MEF2 is found in the same
GAD67-positive populations in development as PGC-1. In the P21
cerebellum (B), a time at which PGC-1 is concentrated in Purkinje
cells and molecular layer (ML) interneurons (see Fig. 7), MEF2 is
concentrated in GAD67-positive Purkinje cells (large cell body in
Purkinje cell layer, PL) and interneurons in the ML (arrowheads), and
GAD67-negative granule cells in the internal granule cell layer (IGL).
In the P21 striatum, PGC-1 immunoreactivity (C1,C3; red) is found
in many neurons, but is most intense in GAD67-positive (green) cells
(arrowheads; C2,C3). Scale bars  100 m in A,C; 25 m in B.
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causes the translocation of GABP subunits to the nucleus
(Yang et al., 2004; Wong-Riley et al., 2005), and putative
GABP-binding sites have been identified on all 10 cyto-
chrome c oxidase promoters in vitro (Ongwijitwat and
Wong-Riley, 2005).
PGC-1 could also regulate metabolism and cellular
energy homeostasis in GABAergic neurons by influencing
glucose transport. Glucose transporter GLUT4 is prefer-
entially expressed in parvalbumin-containing GABAergic
neurons (Apelt et al., 1999), and PGC-1 overexpression
can increase GLUT4 expression in muscle by interacting
with MEF-2C (Michael et al., 2001). This is in line with
PGC-1’s role as a regulator of glucose homeostasis in
other tissues (Rodgers et al., 2005; Wende et al., 2005).
Interestingly, GAD67 has also been shown to be glucose-
responsive in islet- cells of the pancreas and C6 glioma
cells (Pedersen et al., 2001), and dexamethasone, an agent
that stimulates the expression of PGC-1 in liver cells,
can increase GAD67 expression in pancreatic  cells (Kim
et al., 2002).
PGC-1 and GABA in development
The developmental change in PGC-1 localization from
most neurons to mainly GAD67-positive neurons is in-
triguing. Concentration of immunoreactivity for PGC-1
in cell nuclei occurred around the time that GAD67 first
became visible with immunohistochemistry and immuno-
fluorescence. Interestingly, other authors have described a
“precocious” band of GAD67 immunoreactivity that ap-
pears in Layer V of the developing rat cortex between P3
and P9 (Kiser et al., 1998). This pattern was observed for
PGC-1 at P3 (Fig. 3) and P7 (not shown). At present, it is
not known whether PGC-1 can directly influence GAD67
expression or metabolism in GABAergic neurons. Prelim-
inary analyses of gene expression in PGC-1 knockout
animals have revealed a reduction in GAD67 mRNA ex-
pression in whole brain homogenates (unpubl. obs.,
R.M.C., and J. Lin, University of Michigan). It is also
possible that PGC-1 may influence GAD65 expression;
although we did not investigate the developmental regu-
lation of GAD65, it has been reported that GAD65 expres-
sion in the striatum (Greif et al., 1992), cortex (Kiser et al.,
1998), and cerebellum (Greif et al., 1991) is delayed with
respect to GAD67. In fact, the appearance of GAD65 co-
incides with the peak we observed in PGC-1 mRNA ex-
pression. As abnormalities in reelin and GAD65/67-
positive cells have been linked to autism and
schizophrenia (Keverne, 1999; Fatemi, 2005), it would be
interesting to investigate whether disruptions in PGC-1
expression contribute to the progression of these disor-
ders.
In the context of this report, the key issue relates to the
potential function for PGC-1 in GABAergic neurons dur-
ing maturation of the rat brain. A critical step in the
maturation of GABAergic circuitry occurs during the first
3 postnatal weeks, when the postsynaptic response to
GABA changes from excitatory to inhibitory. This change
is proposed to be due to the delayed expression of the
potassium-chloride transporter KCC2 (Rivera et al.,
1999), which when expressed, decreases the intracellular
chloride concentration to favor GABA receptor-mediated
chloride influx and hyperpolarization. There is a marked
increase between P0 and P15 in KCC2 expression in the
rat hippocampus and cortex (Herlenius and Lagercrantz,
2004), with high expression levels of KCC2 corresponding
to a hyperpolarizing GABA response (Rivera et al., 1999).
Interestingly, the temporal profile of KCC2 expression is
very similar to that for PGC-1. At present, it is not clear
how PGC-1 expression in presynaptic GABAergic neu-
rons could influence the postsynaptic response to GABA
and the expression of KCC2. It would be interesting to
speculate that a metabolic boost in GABAergic neurons
influences neurotransmitter release and the strengthen-
ing of synaptic contacts; in this vein, others have reported
that the switch is promoted by activation of GABA recep-
tors, suggesting that the switch could be influenced by
presynaptic GABA release in vivo (Ganguly et al., 2001).
These findings are of particular importance with regard
to the observed behavioral and neuroanatomical pheno-
type of the PGC-1 knockout animals. In one knockout
model (Lin et al., 2004), mice lacking PGC-1 are hyper-
active, showing a 40% increase in the frequency of spon-
taneous movements. Reduced metabolism in GABAergic
neurons due to PGC-1 insufficiency could have a dra-
matic influence on neurotransmission and neuronal sur-
vival, causing postsynaptic overexcitation or excitotoxic-
ity. In fact, PGC-1 knockout animals also exhibit
spongiform-like vacuolizations, most often in the dorsolat-
eral striatum (Lin et al., 2004) and in the vicinity of
pyramidal neurons in Layer V (Leone et al., 2005).
PGC-1 itself may be neuroprotective in GABAergic neu-
rons; PGC-1 can upregulate the expression of antioxi-
dant enzymes (St-Pierre et al., 2003) as well as uncoupling
proteins, which have been shown to protect neurons from
oxidative stress (Andrews et al., 2005). Along these lines,
we found that in the striatum and cerebellum, PGC-1 is
expressed in the same cells as MEF2, a transcription
factor that plays a role in activity-dependent regulation of
neuronal survival (Mao et al., 1999; Okamoto et al., 2002;
Deisseroth et al., 2003).
CONCLUSIONS
These findings implicate PGC-1 as a regulator of neu-
ronal function and GABAergic signaling in rat brain de-
velopment. To determine the functions of PGC-1 more
definitively, one must further characterize the transcrip-
tion factors that are coactivated by PGC-1 in vivo. From
what is known about its roles in nonneuronal cells and its
distribution described here, PGC-1 is a prime candidate
for the transcriptional regulation of metabolism and syn-
aptic plasticity in early postnatal brain development and
may be a good target for the treatment of neurodevelop-
mental and neurodegenerative disorders.
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